197 related articles for article (PubMed ID: 16786129)
21. Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients.
Bümming P; Andersson J; Meis-Kindblom JM; Klingenstierna H; Engström K; Stierner U; Wängberg B; Jansson S; Ahlman H; Kindblom LG; Nilsson B
Br J Cancer; 2003 Aug; 89(3):460-4. PubMed ID: 12888812
[TBL] [Abstract][Full Text] [Related]
22. Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST: preliminary experience from Chang Gung Memorial Hospital.
Yeh CN; Chen TW; Lee HL; Liu YY; Chao TC; Hwang TL; Jan YY; Chen MF
Ann Surg Oncol; 2007 Mar; 14(3):1123-8. PubMed ID: 17195905
[TBL] [Abstract][Full Text] [Related]
23. Gastrointestinal stromal tumours.
Connolly EM; Gaffney E; Reynolds JV
Br J Surg; 2003 Oct; 90(10):1178-86. PubMed ID: 14515284
[TBL] [Abstract][Full Text] [Related]
24. Biology of gastrointestinal stromal tumors.
Corless CL; Fletcher JA; Heinrich MC
J Clin Oncol; 2004 Sep; 22(18):3813-25. PubMed ID: 15365079
[TBL] [Abstract][Full Text] [Related]
25. c-Kit/PDGFRA gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors.
Miselli FC; Casieri P; Negri T; Orsenigo M; Lagonigro MS; Gronchi A; Fiore M; Casali PG; Bertulli R; Carbone A; Pierotti MA; Tamborini E; Pilotti S
Clin Cancer Res; 2007 Apr; 13(8):2369-77. PubMed ID: 17438095
[TBL] [Abstract][Full Text] [Related]
26. Protein expression of KIT and gene mutation of c-kit and PDGFRs in Ewing sarcomas.
Do I; Araujo ES; Kalil RK; Bacchini P; Bertoni F; Unni KK; Park YK
Pathol Res Pract; 2007; 203(3):127-34. PubMed ID: 17298867
[TBL] [Abstract][Full Text] [Related]
27. Analysis of mutation and expression of c-kit and PDGFR-alpha gene in gastrointestinal stromal tumor.
Zheng S; Chen LR; Wang HJ; Chen SZ
Hepatogastroenterology; 2007 Dec; 54(80):2285-90. PubMed ID: 18265649
[TBL] [Abstract][Full Text] [Related]
28. Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity.
Holtkamp N; Okuducu AF; Mucha J; Afanasieva A; Hartmann C; Atallah I; Estevez-Schwarz L; Mawrin C; Friedrich RE; Mautner VF; von Deimling A
Carcinogenesis; 2006 Mar; 27(3):664-71. PubMed ID: 16357008
[TBL] [Abstract][Full Text] [Related]
29. [Gastrointestinal stromal tumor].
Nishida T; Ohmori T; Matsuda H
Gan To Kagaku Ryoho; 2004 Mar; 31(3):331-6. PubMed ID: 15045935
[TBL] [Abstract][Full Text] [Related]
30. Imatinib mesilate for the treatment of gastrointestinal stromal tumour.
Cassier PA; Dufresne A; Arifi S; El Sayadi H; Labidi I; Ray-Coquard I; Tabone S; Méeus P; Ranchère D; Sunyach MP; Decouvelaere AV; Alberti L; Blay JY
Expert Opin Pharmacother; 2008 May; 9(7):1211-22. PubMed ID: 18422477
[TBL] [Abstract][Full Text] [Related]
31. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation.
Antonescu CR; Besmer P; Guo T; Arkun K; Hom G; Koryotowski B; Leversha MA; Jeffrey PD; Desantis D; Singer S; Brennan MF; Maki RG; DeMatteo RP
Clin Cancer Res; 2005 Jun; 11(11):4182-90. PubMed ID: 15930355
[TBL] [Abstract][Full Text] [Related]
32. KIT oncoprotein interactions in gastrointestinal stromal tumors: therapeutic relevance.
Zhu MJ; Ou WB; Fletcher CD; Cohen PS; Demetri GD; Fletcher JA
Oncogene; 2007 Sep; 26(44):6386-95. PubMed ID: 17452978
[TBL] [Abstract][Full Text] [Related]
33. KIT/Val654 Ala receptor detected in one imatinib-resistant GIST patient.
Tamborini E; Gabanti E; Lagonigro MS; Negri T; Pilotti S; Pierotti MA; Pricl S
Cancer Res; 2005 Feb; 65(3):1115; author reply 1115. PubMed ID: 15705916
[No Abstract] [Full Text] [Related]
34. Characteristics of KIT-negative gastrointestinal stromal tumours and diagnostic utility of protein kinase C theta immunostaining.
Lee HE; Kim MA; Lee HS; Lee BL; Kim WH
J Clin Pathol; 2008 Jun; 61(6):722-9. PubMed ID: 18381383
[TBL] [Abstract][Full Text] [Related]
35. Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours.
Hirota S; Nishida T; Isozaki K; Taniguchi M; Nakamura J; Okazaki T; Kitamura Y
J Pathol; 2001 Apr; 193(4):505-10. PubMed ID: 11276010
[TBL] [Abstract][Full Text] [Related]
36. Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression.
Liegl B; Hornick JL; Antonescu CR; Corless CL; Fletcher CD
Am J Surg Pathol; 2009 Feb; 33(2):218-26. PubMed ID: 18830121
[TBL] [Abstract][Full Text] [Related]
37. FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance.
Taylor JR; Brownlow N; Domin J; Dibb NJ
Oncogene; 2006 Jan; 25(1):147-51. PubMed ID: 16170366
[TBL] [Abstract][Full Text] [Related]
38. Activating mutations in c-KIT and PDGFRalpha are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genes.
Burger H; den Bakker MA; Kros JM; van Tol H; de Bruin AM; Oosterhuis W; van den Ingh HF; van der Harst E; de Schipper HP; Wiemer EA; Nooter K
Cancer Biol Ther; 2005 Nov; 4(11):1270-4. PubMed ID: 16294026
[TBL] [Abstract][Full Text] [Related]
39. Merkel cell carcinoma: evaluation of KIT (CD117) expression and failure to demonstrate activating mutations in the C-KIT proto-oncogene - implications for treatment with imatinib mesylate.
Swick BL; Ravdel L; Fitzpatrick JE; Robinson WA
J Cutan Pathol; 2007 Apr; 34(4):324-9. PubMed ID: 17381803
[TBL] [Abstract][Full Text] [Related]
40. [New oncological treatment principle with imatinib].
Kuenen BC; Pinedo HM
Ned Tijdschr Geneeskd; 2003 Oct; 147(42):2044-5. PubMed ID: 14606348
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
